Arrowhead Pharmaceuticals, Inc. (ARWR) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Arrowhead Pharmaceuticals reported revenue of $829.4M, up 23258.2% from $3.6M the year before. Net income was -$1.6M (a -0.2% net margin), or -$0.01 per diluted share. Operating margin was 11.9%. Operating activities generated $179.6M of cash, leaving $156.9M of free cash flow. At fiscal year end, Arrowhead Pharmaceuticals held $1.39B in total assets against $919.2M in total liabilities.
Open the full interactive Arrowhead Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Arrowhead Pharmaceuticals Key Stats
| Share Price | $58.13 |
|---|---|
| Market Cap | $8.33B |
| 52-Week Range | $35.96 – $89.59 |
| Shares Outstanding | 143.4 million (basic, 2026 Q3) |
Arrowhead Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $88.0M | $138.3M | $243.2M | $240.7M | $3.6M | $829.4M |
| Operating Income | -$93.2M | -$149.0M | -$178.5M | -$205.0M | -$601.1M | $98.3M |
| Pre-Tax Income | -$84.6M | -$140.8M | -$172.7M | -$206.5M | -$612.5M | $51.5M |
| Income Tax | $2,400 | $2,000 | $3.8M | $2.8M | -$2.8M | $21.4M |
| Net Income | -$84.6M | -$140.8M | -$176.1M | -$205.3M | -$599.5M | -$1.6M |
| Diluted EPS | -$0.84 | -$1.36 | -$1.67 | -$1.92 | -$5.00 | -$0.01 |
Arrowhead Pharmaceuticals Quarterly Results
| 2025 Q4 | 2026 Q1 | 2026 Q2 | 2026 Q3 | |
|---|---|---|---|---|
| Revenue | $256.5M | $264.0M | $73.7M | $75.3M |
| Net Income | -$23.8M | $30.8M | -$132.7M | -$194.3M |
| Diluted EPS | -$0.18 | $0.22 | -$0.93 | -$1.36 |
Arrowhead Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $143.6M | $184.4M | — | — | — | — |
| Current Assets | $322.4M | $384.6M | $405.3M | $419.5M | $695.5M | $950.6M |
| Total Assets | $522.5M | $710.1M | $691.9M | $765.6M | $1.14B | $1.39B |
| Current Liabilities | $40.7M | $146.5M | $138.8M | $105.5M | $103.2M | $195.5M |
| Total Long-Term Debt | — | — | — | — | $393.2M | $254.9M |
| Total Liabilities | $60.7M | $301.3M | $293.4M | $494.2M | $954.4M | $919.2M |
| Shareholders' Equity | $461.8M | $408.8M | $398.5M | $271.3M | $185.4M | $466.1M |
Arrowhead Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$95.4M | $171.2M | -$136.1M | -$153.9M | -$462.9M | $179.6M |
| Cash From Investing | -$240.8M | -$141.7M | -$5.4M | -$96.2M | -$420.1M | -$129.3M |
| Cash From Financing | $257.9M | $11.3M | $65.2M | $253.1M | $870.5M | $74.0M |
| Free Cash Flow | -$107.4M | $147.7M | -$188.9M | -$330.6M | -$604.3M | $156.9M |
Figures from Arrowhead Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Arrowhead Pharmaceuticals financials page for every line item.
Arrowhead Pharmaceuticals Company Profile
| Ticker | ARWR |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Pasadena, California |
| Incorporated in | Delaware |
| Fiscal Year End | September 30 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0000879407 |
Frequently Asked Questions
What was Arrowhead Pharmaceuticals' revenue in fiscal 2025?
Arrowhead Pharmaceuticals (ARWR) reported revenue of $829.4M for fiscal 2025.
What is Arrowhead Pharmaceuticals' annual revenue history?
Arrowhead Pharmaceuticals' annual revenue by fiscal year: 2020: $88.0M; 2021: $138.3M; 2022: $243.2M; 2023: $240.7M; 2024: $3.6M; 2025: $829.4M.
What was Arrowhead Pharmaceuticals' net income in fiscal 2025?
Arrowhead Pharmaceuticals reported net income of -$1.6M for fiscal 2025.
What was Arrowhead Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Arrowhead Pharmaceuticals' diluted EPS was -$0.01 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Arrowhead Pharmaceuticals generate in fiscal 2025?
Arrowhead Pharmaceuticals generated $156.9M of free cash flow in fiscal 2025.
What was Arrowhead Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q3), Arrowhead Pharmaceuticals reported revenue of $75.3M.
How much debt does Arrowhead Pharmaceuticals have?
Arrowhead Pharmaceuticals reported $254.9M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Arrowhead Pharmaceuticals are outstanding?
Arrowhead Pharmaceuticals reported a weighted average of 143.4 million basic shares outstanding in 2026 Q3.
What is Arrowhead Pharmaceuticals' market cap?
Based on its latest closing price, Arrowhead Pharmaceuticals (ARWR) has a market capitalization of about $8.33B.
When does Arrowhead Pharmaceuticals' fiscal year end?
Arrowhead Pharmaceuticals' fiscal year end, as registered with the SEC, is September 30.
Where is Arrowhead Pharmaceuticals headquartered?
Arrowhead Pharmaceuticals lists its business address in Pasadena, California in its SEC filings.